Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES, 38000 Grenoble, France; LXRepair, 5 Avenue du Grand Sablon, 38700 La Tronche, France.
LXRepair, 5 Avenue du Grand Sablon, 38700 La Tronche, France.
Mutat Res Rev Mutat Res. 2021 Jul-Dec;788:108388. doi: 10.1016/j.mrrev.2021.108388. Epub 2021 Jun 25.
DNA double-strand breaks (DSBs) are highly deleterious lesions, responsible for mutagenesis, chromosomal translocation or cell death. DSB repair (DSBR) is therefore a critical part of the DNA damage response (DDR) to restore molecular and genomic integrity. In humans, this process is achieved through different pathways with various outcomes. The balance between DSB repair activities varies depending on cell types, tissues or individuals. Over the years, several methods have been developed to study variations in DSBR capacity. Here, we mainly focus on functional techniques, which provide dynamic information regarding global DSB repair proficiency or the activity of specific pathways. These methods rely on two kinds of approaches. Indirect techniques, such as pulse field gel electrophoresis (PFGE), the comet assay and immunofluorescence (IF), measure DSB repair capacity by quantifying the time-dependent decrease in DSB levels after exposure to a DNA-damaging agent. On the other hand, cell-free assays and reporter-based methods directly track the repair of an artificial DNA substrate. Each approach has intrinsic advantages and limitations and despite considerable efforts, there is currently no ideal method to quantify DSBR capacity. All techniques provide different information and can be regarded as complementary, but some studies report conflicting results. Parameters such as the type of biological material, the required equipment or the cost of analysis may also limit available options. Improving currently available methods measuring DSBR capacity would be a major step forward and we present direct applications in mechanistic studies, drug development, human biomonitoring and personalized medicine, where DSBR analysis may improve the identification of patients eligible for chemo- and radiotherapy.
DNA 双链断裂 (DSB) 是高度有害的损伤,可导致突变、染色体易位或细胞死亡。因此,DSB 修复 (DSBR) 是 DNA 损伤反应 (DDR) 的关键部分,可恢复分子和基因组的完整性。在人类中,这个过程通过不同的途径和不同的结果来实现。DSBR 活性的平衡取决于细胞类型、组织或个体。多年来,已经开发出几种方法来研究 DSBR 能力的变化。在这里,我们主要关注功能技术,这些技术提供了有关全局 DSB 修复效率或特定途径活性的动态信息。这些方法依赖于两种方法。间接技术,如脉冲场凝胶电泳 (PFGE)、彗星试验和免疫荧光 (IF),通过定量暴露于 DNA 损伤剂后 DSB 水平随时间的下降来测量 DSB 修复能力。另一方面,无细胞测定和基于报告基因的方法直接跟踪人工 DNA 底物的修复。每种方法都有其内在的优点和局限性,尽管做了相当大的努力,但目前还没有一种理想的方法来量化 DSBR 能力。所有技术都提供不同的信息,可以被视为互补的,但有些研究报告结果相互矛盾。诸如生物材料的类型、所需设备或分析成本等参数也可能限制可用的选择。改进目前用于测量 DSBR 能力的方法将是向前迈出的重要一步,我们提出了在机制研究、药物开发、人体生物监测和个性化医学中的直接应用,其中 DSBR 分析可能有助于识别有资格接受化疗和放疗的患者。